MedTrace Logo

A Study of AMC6156 in People With Sarcopenia

NCT07072195 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-07-29

No results posted yet for this study

Summary

This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.

Conditions

Interventions

DRUG

AMC6156 0.1mg

Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.

DRUG

AMC6156 0.3mg

Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.

DRUG

AMC6156 1.0mg

Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.

DRUG

Placebo

Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.

Sponsors & Collaborators

  • Animuscure Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-03-31
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07072195 on ClinicalTrials.gov